# Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)

> **NCT06527534** · PHASE4 · RECRUITING · sponsor: **Universita di Verona** · enrollment: 30 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Filgotinib
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT06527534
- **Lead sponsor:** Universita di Verona
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-15
- **Primary completion:** 2025-07-15
- **Final completion:** 2025-09-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06527534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06527534, "Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06527534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*